Ultragenyx Pharmaceutical Inc. RARE
Analyst Ratings
- Consensus
- Buy — 16 Buy · 2 Hold · 0 Sell (18 analysts)
- Avg. Price Target
- $56.50 (+113.3% upside)
Key Stats
- Today's Range
- $25.75 – $26.58
- 50-Day Range
- $21.39 – $36.57
- 52-Week Range
- $18.29 – $39.89
- Volume
- 1.22 million shs
- Average Volume
- 1.95 million shs
- Market Cap
- $2.65 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- -9.10
- Price / Sales
- 3.69
Short Interest
- Short Interest
- 5.60%
- Days to Cover
- 14.38
Financials (TTM)
- Revenue
- $717.21 million
- Net Income
- $-585,969,000
- Net Margin
- -81.70%
- Return on Equity
- 201.36%
- Debt-to-Equity
- —
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Related Stocks
Compare head-to-head: RARE vs LLY·RARE vs JNJ·RARE vs ABBV·RARE vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.